Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: Protalix is a development-stage biopharmaceutical company focused on the ProCellEx protein expression system. Its lead product candidate is UPLYSO (prGCD) for the treatment of Gaucher disease. In September 2009, the company successfully completed its Phase III pivotal study for UPLYSO and received Fast Track Designation and Orphan Drug Status from the FDA.
Key Financial Metrics
| Metric | Nine Months Ended Sep 30, 2009 | Three Months Ended Sep 30, 2009 | Balance Sheet (Sep 30, 2009) |
|---|---|---|---|
| Revenues | $830,000 | $0 | N/A |
| Net Loss | $(16,504,000) | $(5,894,000) | N/A |
| Operating Loss | $(16,954,000) | $(6,046,000) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $22,610,000 |
| Total Assets | N/A | N/A | $38,120,000 |
| Total Liabilities | N/A | N/A | $8,043,000 |
| Accumulated Deficit | N/A | N/A | $(91,514,000) |
| Net Cash Used in Operating Activities | $(14,666,000) | N/A | N/A |
| Net Cash Used in Investing Activities | $(5,633,000) | N/A | N/A |
Note: All figures in thousands of U.S. dollars unless otherwise noted. The company reported minimal revenue of $830,000 for the nine-month period, primarily from non-core activities, as it remains in the development stage.
Material Changes vs. Prior Period
- Research & Development (R&D): For the nine months ended September 30, 2009, R&D expenses increased by 9.5% to $17.3 million compared to $15.8 million in the prior year period. This increase was driven by $1.3 million in additional costs for consulting and subcontractors related to the Phase III clinical trial, partially offset by an increase in government grants.
- General & Administrative (G&A): G&A expenses decreased by 28.3% to $3.8 million for the nine-month period, down from $5.3 million in the prior year. The reduction was primarily due to a $704,000 decrease in share-based compensation as certain stock options were fully expensed in 2008.
- Financial Income: Net financial income decreased by 80.0% to $450,000 for the nine-month period, compared to $2.0 million in the prior year. This decline resulted from the devaluation of the U.S. dollar against the New Israeli Shekel (NIS) and lower interest rates on deposits.
- Liquidity: Cash and cash equivalents decreased from $42.6 million at December 31, 2008, to $22.6 million at September 30, 2009, reflecting significant cash burn from operations and capital expenditures.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring losses until UPLYSO is approved. The company anticipates submitting a New Drug Application (NDA) for UPLYSO on a rolling basis before the end of 2009. R&D expenses are expected to remain consistent until approval.
- Liquidity Position: Based on current cash resources, the company believes it can fund operations for approximately 15 months. However, additional financing may be required sooner if expenses increase unexpectedly or if the company accelerates commercialization efforts.
- Capital Needs: Future funding will likely be sought through corporate collaborations, licensing arrangements, or public/private equity offerings. The company currently has no commitments for future external funding.
- Risks: Key risks include the inherent uncertainties of drug development, potential delays or rejection of regulatory applications, inability to secure additional financing, and the risk that clinical trial results may not support approval. The company also faces currency risk as approximately 35% of costs are incurred in NIS.
- Unusual Items: The company recognized a cumulative effect of a change in accounting principle of $(37,000) in the nine-month period. Share-based compensation totaled $2.0 million for the period.
Investor Verification Checklist
- Regulatory Timeline: Verify the status of the rolling NDA submission for UPLYSO and the expected timeline for FDA review and potential approval.
- Cash Runway: Confirm the 15-month liquidity estimate against current burn rates and any potential acceleration of capital expenditures for manufacturing upgrades.
- Grant Dependency: Assess the sustainability of R&D funding given the reliance on government grants (e.g., from the Office of the Chief Scientist) which offset a significant portion of expenses.
- Currency Exposure: Monitor the exchange rate between the U.S. dollar and the New Israeli Shekel, as fluctuations materially impact financial income and operating costs.
- Dilution Risk: Review the company's capital raising plans, as future equity offerings will likely result in significant dilution to existing shareholders.